Vulvovaginal candidiasis from non-albicans species: retrospective study of recurrence rate after fluconazole therapy
- PMID: 16846086
Vulvovaginal candidiasis from non-albicans species: retrospective study of recurrence rate after fluconazole therapy
Abstract
Objective: To investigate the recurrence rate of vulvovaginal candidiasis from non-albicans species after fluconazole therapy.
Study design: A retrospective cohort of 127 patients with symptomatic vulvovaginal candidiasis by nonalbicans species referred from primary care physicians were evaluated between 1995 and 2004. Complete history, physical examination, basic metabolic panel, and bacterial and fungal cultures were performed. All patients received a daily dose of fluconazole for 30 days. Follow-up evaluations were done at 1, 3, 6, and 12 months.
Results: The recurrence rate for all non-albicans vulvovaginitis was 40.2%, 46.5%, 50.4% and 54.2% at 1, 3, 6, and 12 months, respectively. Patients with symptomatic recurrences were more likely to be younger than 35 years of age, older than 65, nulliparous and fastidious vulvar cleaners and were more likely to have concomitant bacterial infections.
Conclusion: The recurrence rate of symptomatic vulvovaginal candidiasis colonized by non-albicans species after fluconazole therapy was 50.4% at 6 months and 54.2% at 12 months. Nulliparity and age <35 or > 65 years and fastidious vulvar cleaning were positively associated with symptomatic recurrent episodes.
Similar articles
-
Post-menopausal recurrent vaginal candidiasis: effect of hysterectomy on response to treatment, type of colonization and recurrence rates post-treatment.Maturitas. 2005 Jul 16;51(3):294-8. doi: 10.1016/j.maturitas.2004.08.012. Maturitas. 2005. PMID: 15978973
-
Individualized decreasing-dose maintenance fluconazole regimen for recurrent vulvovaginal candidiasis (ReCiDiF trial).Am J Obstet Gynecol. 2008 Dec;199(6):613.e1-9. doi: 10.1016/j.ajog.2008.06.029. Epub 2008 Oct 30. Am J Obstet Gynecol. 2008. PMID: 18976735
-
Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis.N Engl J Med. 2004 Aug 26;351(9):876-83. doi: 10.1056/NEJMoa033114. N Engl J Med. 2004. PMID: 15329425 Clinical Trial.
-
Treatment of recurrent vulvovaginal candidiasis.Am Fam Physician. 2000 Jun 1;61(11):3306-12, 3317. Am Fam Physician. 2000. PMID: 10865926 Review.
-
Recurrent vulvovaginal candidiasis.Mo Med. 2006 Mar-Apr;103(2):165-8. Mo Med. 2006. PMID: 16703718 Review.
Cited by
-
Chronic vulvar irritation: could toilet paper be the culprit?Can Fam Physician. 2010 Apr;56(4):350-2. Can Fam Physician. 2010. PMID: 20393094 Free PMC article. No abstract available.
-
Antifungal drug discovery through the study of invertebrate model hosts.Curr Med Chem. 2009;16(13):1588-95. doi: 10.2174/092986709788186237. Curr Med Chem. 2009. PMID: 19442135 Free PMC article. Review.
-
NDV-3 protects mice from vulvovaginal candidiasis through T- and B-cell immune response.Vaccine. 2013 Nov 12;31(47):5549-56. doi: 10.1016/j.vaccine.2013.09.016. Epub 2013 Sep 21. Vaccine. 2013. PMID: 24063977 Free PMC article.
-
Lamisil versus clotrimazole in the treatment of vulvovaginal candidiasis.Iran J Microbiol. 2013 Mar;5(1):86-90. Iran J Microbiol. 2013. PMID: 23466900 Free PMC article.
-
Comparative Analysis of the Capacity of the Candida Species To Elicit Vaginal Immunopathology.Infect Immun. 2018 Nov 20;86(12):e00527-18. doi: 10.1128/IAI.00527-18. Print 2018 Dec. Infect Immun. 2018. PMID: 30249743 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources